Last reviewed · How we verify
Treatment and prophylaxis
This drug works by inhibiting the replication of the human immunodeficiency virus (HIV).
This drug works by inhibiting the replication of the human immunodeficiency virus (HIV). Used for Treatment and prophylaxis of HIV-1 infection, Prevention of mother-to-child transmission of HIV.
At a glance
| Generic name | Treatment and prophylaxis |
|---|---|
| Sponsor | Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia |
| Drug class | NRTI (nucleoside reverse transcriptase inhibitor) |
| Target | Reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
It does this by targeting the viral enzyme reverse transcriptase, preventing the virus from replicating and reducing the viral load in the body. This leads to a decrease in the severity of symptoms and a reduction in the risk of transmission to others.
Approved indications
- Treatment and prophylaxis of HIV-1 infection
- Prevention of mother-to-child transmission of HIV
Common side effects
- Nausea
- Headache
- Fatigue
- Diarrhea
- Abdominal pain
Key clinical trials
- Screening and Multiple Intervention on Lung Epidemics (PHASE2)
- A Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer (PHASE2)
- A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) (PHASE3)
- Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies (PHASE2)
- Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer (PHASE2)
- Metformin Hydrochloride in Preventing Oral Cancer in Patients With an Oral Premalignant Lesion (PHASE2)
- A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events (NA)
- Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: